All In Biotech

Drug Trial Radar · NCT02779738

A Study of Merestinib (LY2801653) in Healthy Participants

The Effect of Food on the Bioavailability of Merestinib in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

May 2016

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
May 20, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of food on merestinib (standard meal and high-fat meal) compared to the fasted state. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In addition, the tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. The study will last approximately 28 days. Screening is required within 28 days prior to the start of the study.

Conditions

  • Healthy

Interventions

  • MerestinibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) for Merestinib for High-Fat Meal and Fasted StateTime frame: Predose through 120 hours after administration of study drug
  2. Pharmacokinetics: Maximum Concentration (Cmax) for Merestinib for Standard Meal and Fasted StateTime frame: Predose through 120 hours after administration of study drug
  3. Pharmacokinetics: Area Under The Concentration Curve AUC(0-∞) for Merestinib for High-Fat Meal and Fasted StateTime frame: Predose through 120 hours after administration of study drug
  4. Pharmacokinetics: Area Under The Concentration Curve AUC(0-∞) for Merestinib for Standard Meal and Fasted StateTime frame: Predose through 120 hours after administration of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Inc

    Daytona Beach, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.